Physician profile
Marc Levitt
NPI 1043217987
$6,024.37
in general payments reported to CMS, 2019-2025
39 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $977 · 2022: $688 · 2023: $1,482 · 2024: $2,236 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,221.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,013.80 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $658.19 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $576.37 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $561.96 | 2023-2025 | Gemtesa |
| Abbvie INC. | $339.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.96 | 2022-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $287.57 | 2024-2025 | Dupixent |
| Esperion Therapeutics, INC. | $187.91 | 2021 | |
| Abbott Laboratories | $182.74 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $152.65 | 2021-2022 | |
| Corium, LLC | $150.73 | 2023 | Adlarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.19 | 2022-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $148.61 | 2023-2025 | Cologuard Collection Kit |
| Phadia US INC. | $147.32 | 2023-2024 | Immunocap |
| Novartis Pharmaceuticals Corporation | $144.72 | 2022-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $138.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.49 | 2023 | |
| Janssen Pharmaceuticals, INC | $89.18 | 2021-2022 | |
| Lilly USA, LLC | $82.35 | 2021-2025 | Zepbound, Mounjaro, Emgality |
| Paratek Pharmaceuticals, INC. | $81.30 | 2022-2023 | Nuzyra |
| Amarin Pharma, INC. | $61.96 | 2021 | |
| Pfizer INC. | $47.06 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $42.61 | 2021-2023 | Verquvo, Steglatro |
| Renalytix Ai, INC. | $38.04 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Daiichi Sankyo INC. | $37.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.54 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.62 | 2022 | |
| Eisai INC. | $28.51 | 2021 | |
| Lundbeck LLC | $24.77 | 2024 | Rexulti |
| Dexcom, INC. | $24.26 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.85 | 2022 | |
| Astellas Pharma US INC | $23.11 | 2024 | Veozah |
| Ardelyx, INC. | $20.99 | 2024 | Ibsrela |
| Alfasigma USA, INC. | $18.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.18 | 2023 | Quviviq |
| Shield Therapeutics INC | $16.68 | 2024 | |
| Radius Health, INC. | $14.95 | 2023 | Tymlos |
| Vistapharm, INC. | $13.84 | 2021 | |
| Medicure Pharma INC. | $13.75 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.